CLL Coverage from Every Angle

Nitin Jain, MD, on Evolving Treatment Paradigms

Posted: Monday, October 7, 2019

In view of new drug approvals and new indications for first-line therapy of CLL, how are subsequent treatment paradigms in relapsed/refractory settings likely to evolve?

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.